Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4052408 | 0.97 | GNRHR (0.81) | GNRHRKCNH2 | |
| SCHEMBL4053795 | 0.96 | GNRHR (0.80) | GNRHRKCNH2 | |
| SCHEMBL4054247 | 0.95 | GNRHR (0.79) | GNRHRKCNH2 | |
| SCHEMBL6645334 | 0.95 | GNRHR (0.78) | GNRHRKCNH2 | |
| SCHEMBL13722346 | 0.95 | GNRHR (0.78) | GNRHRKCNH2 | |
| SCHEMBL4057278 | 0.95 | GNRHR (0.78) | GNRHRKCNH2 | |
| SCHEMBL13721581 | 0.94 | GNRHR (0.77) | GNRHRKCNH2 | |
| SCHEMBL4051462 | 0.94 | GNRHR (0.79) | GNRHRKCNH2 | |
| SCHEMBL4051550 | 0.94 | GNRHR (0.81) | GNRHR | |
| SCHEMBL4061793 | 0.94 | GNRHR (0.76) | GNRHRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050222174-A1 | Thienopyrimidines, process for preparing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-10-06 | — | — | US | claimed |
| US-7569570-B2 | Thienopyrimidines, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569570-B2 | Thienopyrimidines, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569570-B2 | Thienopyrimidines, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20050222174-A1 | Thienopyrimidines, process for preparing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1479684-A1 | THIENOPYRIMIDINES, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222174-A1 | Thienopyrimidines, process for preparing the same and use thereof | GNRHR, CRH, CYP19A1 | GNRHR 1/4885KCNH2 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.